Glioblastoma: Emerging Treatments and Novel Trial Designs
Management of glioblastoma is a clinical challenge since very few systemic treatments have shown clinical efficacy in recurrent disease. Thanks to an increased knowledge of the biological and molecular mechanisms related to disease progression and growth, promising novel treatment strategies are eme...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/15/3750 |
id |
doaj-941f73dc5f21479aae0a2b3373dd6d7a |
---|---|
record_format |
Article |
spelling |
doaj-941f73dc5f21479aae0a2b3373dd6d7a2021-08-06T15:20:23ZengMDPI AGCancers2072-66942021-07-01133750375010.3390/cancers13153750Glioblastoma: Emerging Treatments and Novel Trial DesignsVincenzo Di Nunno0Enrico Franceschi1Alicia Tosoni2Lidia Gatto3Raffaele Lodi4Stefania Bartolini5Alba Ariela Brandes6Department of Oncology, AUSL Bologna, Via Altura 3, 40139 Bologna, ItalyDepartment of Oncology, AUSL Bologna, Via Altura 3, 40139 Bologna, ItalyDepartment of Oncology, AUSL Bologna, Via Altura 3, 40139 Bologna, ItalyDepartment of Oncology, AUSL Bologna, Via Altura 3, 40139 Bologna, ItalyIstituto delle Scienze Neurologiche di Bologna, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 40139 Bologna, ItalyDepartment of Oncology, AUSL Bologna, Via Altura 3, 40139 Bologna, ItalyDepartment of Oncology, AUSL Bologna, Via Altura 3, 40139 Bologna, ItalyManagement of glioblastoma is a clinical challenge since very few systemic treatments have shown clinical efficacy in recurrent disease. Thanks to an increased knowledge of the biological and molecular mechanisms related to disease progression and growth, promising novel treatment strategies are emerging. The expanding availability of innovative compounds requires the design of a new generation of clinical trials, testing experimental compounds in a short time and tailoring the sample cohort based on molecular and clinical behaviors. In this review, we focused our attention on the assessment of promising novel treatment approaches, discussing novel trial design and possible future fields of development in this setting.https://www.mdpi.com/2072-6694/13/15/3750glioblastomanewly diagnosed glioblastomarecurrent glioblastomaGBMnew trial design |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Vincenzo Di Nunno Enrico Franceschi Alicia Tosoni Lidia Gatto Raffaele Lodi Stefania Bartolini Alba Ariela Brandes |
spellingShingle |
Vincenzo Di Nunno Enrico Franceschi Alicia Tosoni Lidia Gatto Raffaele Lodi Stefania Bartolini Alba Ariela Brandes Glioblastoma: Emerging Treatments and Novel Trial Designs Cancers glioblastoma newly diagnosed glioblastoma recurrent glioblastoma GBM new trial design |
author_facet |
Vincenzo Di Nunno Enrico Franceschi Alicia Tosoni Lidia Gatto Raffaele Lodi Stefania Bartolini Alba Ariela Brandes |
author_sort |
Vincenzo Di Nunno |
title |
Glioblastoma: Emerging Treatments and Novel Trial Designs |
title_short |
Glioblastoma: Emerging Treatments and Novel Trial Designs |
title_full |
Glioblastoma: Emerging Treatments and Novel Trial Designs |
title_fullStr |
Glioblastoma: Emerging Treatments and Novel Trial Designs |
title_full_unstemmed |
Glioblastoma: Emerging Treatments and Novel Trial Designs |
title_sort |
glioblastoma: emerging treatments and novel trial designs |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2021-07-01 |
description |
Management of glioblastoma is a clinical challenge since very few systemic treatments have shown clinical efficacy in recurrent disease. Thanks to an increased knowledge of the biological and molecular mechanisms related to disease progression and growth, promising novel treatment strategies are emerging. The expanding availability of innovative compounds requires the design of a new generation of clinical trials, testing experimental compounds in a short time and tailoring the sample cohort based on molecular and clinical behaviors. In this review, we focused our attention on the assessment of promising novel treatment approaches, discussing novel trial design and possible future fields of development in this setting. |
topic |
glioblastoma newly diagnosed glioblastoma recurrent glioblastoma GBM new trial design |
url |
https://www.mdpi.com/2072-6694/13/15/3750 |
work_keys_str_mv |
AT vincenzodinunno glioblastomaemergingtreatmentsandnoveltrialdesigns AT enricofranceschi glioblastomaemergingtreatmentsandnoveltrialdesigns AT aliciatosoni glioblastomaemergingtreatmentsandnoveltrialdesigns AT lidiagatto glioblastomaemergingtreatmentsandnoveltrialdesigns AT raffaelelodi glioblastomaemergingtreatmentsandnoveltrialdesigns AT stefaniabartolini glioblastomaemergingtreatmentsandnoveltrialdesigns AT albaarielabrandes glioblastomaemergingtreatmentsandnoveltrialdesigns |
_version_ |
1721218828214468608 |